These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8398589)

  • 1. Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects.
    De Boer A; Kluft C; Kasper FJ; Kroon JM; Schoemaker HC; Breimer DD; Soons PA; Cohen AF
    Br J Clin Pharmacol; 1993 Aug; 36(2):99-104. PubMed ID: 8398589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator.
    de Boer A; Kluft C; Kroon JM; Kasper FJ; Schoemaker HC; Pruis J; Breimer DD; Soons PA; Emeis JJ; Cohen AF
    Thromb Haemost; 1992 Jan; 67(1):83-7. PubMed ID: 1615490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of nifedipine and captopril on liver blood flow in healthy subjects.
    Burggraaf J; Schoemaker RC; Kroon JM; Cohen AF
    Br J Clin Pharmacol; 1998 May; 45(5):447-51. PubMed ID: 9643616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
    van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
    Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Influence of acute hypertriglyceridemia on plasma t-PA in healthy male volunteers.
    Kemme MJ; Burggraaf J; Schoemaker RC; Cohen AF
    Thromb Res; 2001 Jul; 103(1):9-16. PubMed ID: 11434941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
    Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of 1-desamino-8-D-vasopressin on endogenous fibrinolysis, haemodynamics and liver blood flow in healthy subjects.
    Burggraaf J; Schoemaker HC; Kroon JM; Huisman L; Kluft C; Cohen AF
    Clin Sci (Lond); 1994 May; 86(5):497-503. PubMed ID: 8033503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splanchnic extraction and clearance of tissue plasminogen activator (t-PA) after injection of recombinant t-PA (Actilyse) in resting healthy subjects is proportional to the arterial concentration.
    Jørgensen M; Tønnesen KH; Petersen KR; Jespersen J; Gram J; Vinberg N
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):331-8. PubMed ID: 12032399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of submaximal exercise on fibrinolysis.
    Fras Z; Keber D; Chandler WL
    Blood Coagul Fibrinolysis; 2004 Apr; 15(3):227-34. PubMed ID: 15060418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarction.
    van Griensven JM; Koster RW; Hopkins GR; Beier H; Günzler WA; Kroon R; Schoemaker RC; Cohen AF
    Thromb Haemost; 1997 Sep; 78(3):1015-20. PubMed ID: 9308746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of diltiazem on the pharmacokinetics of nifedipine.
    Ohashi K; Tateishi T; Sudo T; Sakamoto K; Toyosaki N; Hosoda S; Toyo-oka T; Sugimoto K; Kumagai Y; Ebihara A
    J Cardiovasc Pharmacol; 1990 Jan; 15(1):96-101. PubMed ID: 1688989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
    de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
    Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and effects on fibrinolytic and coagulation parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers.
    Verstraete M; Su CA; Tanswell P; Feuerer W; Collen D
    Thromb Haemost; 1986 Aug; 56(1):1-5. PubMed ID: 3095944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
    Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of changing liver blood flow by exercise and food on kinetics and dynamics of saruplase.
    van Griensven JM; Burggraaf KJ; Gerloff J; Günzler WA; Beier H; Kroon R; Huisman LG; Schoemaker RC; Kluft K; Cohen AF
    Clin Pharmacol Ther; 1995 Apr; 57(4):381-9. PubMed ID: 7712665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers.
    Walley TJ; Heagerty AM; Woods KL; Bing RF; Pohl JE; Barnett DB
    Br J Clin Pharmacol; 1987 Jun; 23(6):693-701. PubMed ID: 3606929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice.
    Lansink M; Jong M; Bijsterbosch M; Bekkers M; Toet K; Havekes L; Emeis J; Kooistra T
    Blood; 1999 Aug; 94(4):1330-6. PubMed ID: 10438721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of felodipine and nifedipine on hepatic and forearm blood flow in healthy men.
    Bengtsson-Hasselgren B; Rönn O; Blychert LO; Edgar B; Raner S
    Eur J Clin Pharmacol; 1990; 38(6):529-33. PubMed ID: 2373126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
    Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC
    Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
    Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.